Conversely, KRAS mutations are present in only approximately 30% of lung adenocarcinomas [6], while EGFR mutations occur in 10-15% of non-Asian and up to 50% of Asian patients with non-small cell lung cancer (NSCLC) [7]. This evidence concerns the gene EGFR and lung adenocarcinoma.